Wall Street Zen Upgrades vTv Therapeutics (NASDAQ:VTVT) to “Hold”

vTv Therapeutics (NASDAQ:VTVT) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday.

Several other research analysts have also recently issued reports on VTVT. TD Cowen initiated coverage on shares of vTv Therapeutics in a report on Monday, January 5th. They issued a “buy” rating on the stock. HC Wainwright reiterated a “buy” rating and set a $47.00 price target (up from $36.00) on shares of vTv Therapeutics in a report on Friday, December 19th. Roth Mkm started coverage on shares of vTv Therapeutics in a research report on Thursday, January 22nd. They set a “buy” rating and a $58.00 price target for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of vTv Therapeutics in a report on Monday, December 29th. Finally, BTIG Research restated a “buy” rating and issued a $49.00 price objective on shares of vTv Therapeutics in a research report on Wednesday. Five analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $53.00.

vTv Therapeutics Price Performance

Shares of VTVT stock opened at $33.28 on Friday. The business has a 50-day moving average of $35.93 and a 200 day moving average of $29.60. vTv Therapeutics has a 1-year low of $14.00 and a 1-year high of $44.00. The stock has a market capitalization of $131.12 million, a PE ratio of -9.93 and a beta of 0.44.

vTv Therapeutics (NASDAQ:VTVT) last announced its quarterly earnings results on Tuesday, March 10th. The biotechnology company reported ($0.58) EPS for the quarter, topping analysts’ consensus estimates of ($1.09) by $0.51. The company had revenue of ($0.02) million during the quarter.

Hedge Funds Weigh In On vTv Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Baker BROS. Advisors LP boosted its holdings in vTv Therapeutics by 52.4% in the third quarter. Baker BROS. Advisors LP now owns 148,314 shares of the biotechnology company’s stock valued at $3,463,000 after acquiring an additional 51,000 shares in the last quarter. Geode Capital Management LLC increased its position in vTv Therapeutics by 84.3% during the 4th quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company’s stock valued at $1,128,000 after purchasing an additional 12,896 shares during the period. 683 Capital Management LLC bought a new position in vTv Therapeutics in the 4th quarter worth $731,000. Finally, Goldman Sachs Group Inc. bought a new position in vTv Therapeutics in the 4th quarter worth $221,000. Institutional investors own 17.51% of the company’s stock.

Key Headlines Impacting vTv Therapeutics

Here are the key news stories impacting vTv Therapeutics this week:

• Positive Sentiment: Evercore ISI initiated coverage with an “Outperform” recommendation, providing a new institutional buy-side endorsement that can attract demand and support the share price. Evercore initiation article
• Positive Sentiment: HC Wainwright reiterated a “Buy” rating and $47 price target while raising several near-term EPS estimates (Q1–Q4 2026 and FY2026) and trimming losses for FY2027 relative to prior forecasts — a signal that the firm sees improving fundamentals in the nearer term and provides supportive analyst cover (no link available).
• Neutral Sentiment: vTv filed Q4 and full-year 2025 financial results and issued a corporate update; company results and commentary can influence sentiment depending on guidance and program milestones, so investors should review the release for pipeline/cash details. Q4/FY2025 results and corporate update
• Neutral Sentiment: Market calendars show vTv is projected to announce upcoming earnings — scheduled event risk can increase intraday volatility around the stock. Earnings projection article
• Negative Sentiment: Within the same HC Wainwright coverage notes, the firm lowered long‑range EPS assumptions (FY2028–FY2030 and FY2029 reductions), increasing projected longer-term losses. Those cuts could pressure expectations for longer-term profitability and cap upside despite near-term improvements (no link available).

vTv Therapeutics Company Profile

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.